Document is current
Any future updates will be listed below
-
Authors
Dai, Yibo https://orcid.org/0009-0007-8023-4665
Kizhakeyil, Atish
Chihara, Dai
Li, Xubin
Liu, Yunhe
Sainz Zuniga, Tania Patricia
Wilson, Ashley
Henderson, Jared https://orcid.org/0000-0002-5121-5234
Vibe, Daniil https://orcid.org/0000-0002-0175-1127
Petrosyants, Arman
Jacobson, Connor https://orcid.org/0000-0002-0299-3451
Sarachakov, Alexander
Nomie, Krystle
Kryukov, Kirill
Bagaev, Aleksander
Chauhan, Ayushi
Westin, Jason R.
Flowers, Christopher R.
Vega, Francisco https://orcid.org/0000-0001-5956-452X
Wang, Linghua https://orcid.org/0000-0001-9380-0266
Green, Michael R. https://orcid.org/0000-0001-6309-9472
-
Funding
Funding for this research was provided by:
Leukemia and Lymphoma Society (NA)
Lymphoma Research Foundation (NA)
- License Information
-
More Information
Article History
Received: 19 October 2024
Accepted: 28 August 2025
First Online: 21 October 2025
Competing interests
: D.C. reports research funding from Genmab, BMS, MorPhosys, Ipsen and ONO Pharmaceutical; honoraria from ONO Pharmaceutical and BeiGene. D.W., A.P., C.J., A.S., K.N. and A.B. are employees of BostonGene Corporation. J.W. reports research funding or advisory board membership with AbbVie, ADC Therapeutics, Allogene, AstraZeneca, BMS, Genentech, Janssen, Kite/Gilead, Morphosys/Incyte, Novartis, Nurix, Pfizer and Regeneron. C.R.F. reports consulting for AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, N-Power Medicine, Pharmacyclics/Janssen, SeaGen and Spectrum; research funding from 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation and the Cancer Prevention and Research Institute of Texas; and stock options in Foresight Diagnostics and N-Power Medicine. M.R.G. reports research funding from Sanofi, Kite/Gilead, AbbVie and Allogene; Advisory board or consulting for AbbVie, Allogene, Arvinas, Desai, Bristol Myers Squibb and Johnson & Johnson; honoraria from Daiichi Sankyo and DAVA Oncology; and stock ownership of Melbridge Therapeutics and Shenandoah Therapeutics. The remaining authors declare no competing interests.
